Researchers analyzed data from 108,647 postmenopausal women diagnosed with breast cancer to see if there was an increased risk of the disease for those who used menopausal hormone therapy.
Nancy Davidson, MD, from Seattle Cancer Care Alliance and Fred Hutchinson Research Center, discussed advancements in breast cancer.
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.
Research suggests that there is an association between breast cancer risk and the use of chemical straighteners and permanent hair dyes.
The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.
Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer.
Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.
Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24.
Oncotype DX® Breast Recurrence Scores from the National Cancer Database indicated that a lower threshold is needed for male patients with early stage ER-positive breast cancer to predict mortality.
A quality improvement study indicated that nudges in the electronic health record were associated with a significant increase in clinician ordering of screening tests for breast and colorectal cancer.